Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Nabi Biopharma Sells Aloprim Product to Bioniche Teoranta | Contract Pharma

What are you searching for?

Sign in
Breaking News

Nabi Biopharma Sells Aloprim Product to Bioniche Teoranta

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Nabi Biopharmaceuticals has executed a definitive agreement to sell its Aloprim for Injection product to Bioniche Teoranta for $3.7 million. Bioniche Teoranta is based in Ireland and is part of Bioniche Pharma Group. The transaction, subject to customary closing conditions, is expected to close during the second quarter.

“When we recently announced our intent to form two strategic business units, Nabi Biologics and Nabi Pharmaceuticals, we determined Aloprim was no longer a strategic component of our product portfolio,” said Dr. Leslie Hudson, interim president and chief executive officer of Nabi. “This sale marks another step for Nabi toward the realization of our strategic plan.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters